research use only
Cat.No.S2197
| Related Targets | HDAC ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase eIF |
|---|---|
| Other PARP Inhibitors | XAV-939 AZD5305 (Saruparib) Veliparib (ABT-888) PJ34 HCl AG-14361 Iniparib (BSI-201) G007-LK Pamiparib UPF 1069 Stenoparib (E7449) |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| C41 cells | Function assay | Inhibition of PARP1 in human C41 cells by FITC-conjugated DAPI staining, EC50=0.001 μM | ||||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 33 mg/mL
(101.74 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 324.35 | Formula | C18H17FN4O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 934162-61-5 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1CC(NC1)C2=CC(=C(C=C2)C3=NC4=C(C=CC=C4N3)C(=O)N)F | ||
| Features |
A promising, structurally diverse benzimidazole analogue that is being further characterized preclinically.
|
|---|---|
| Targets/IC50/Ki |
PARP1
(Cell-free assay) 1 nM(Ki)
PARP1
(a whole cell assay) 1 nM(EC50)
PARP2
(Cell-free assay) 1.5 nM(Ki)
|
| In vitro |
A-966492 is one of the most potent PARP inhibitors. This compound displays excellent potency against the PARP-1 enzyme with a Kiof 1 nM and an EC50 of 1 nM in a whole cell assay. It significantly enhances the efficacy of TMZ in a dose-dependent manner. In addition, this chemical is orally bioavailable across multiple species, crosses the blood−brain barrier, and appears to distribute into tumor tissue. It represents a promising, structurally diverse benzimidazole analogue and is being further characterized preclinically. |
| Kinase Assay |
PARP Enzyme Assay
|
|
The enzyme assay is conducted in buffer containing 50 mM Tris, pH 8.0, 1 mM dithiothreitol(DTT), and 4 mM MgCl2. PARP reactions contains 1.5 μM [3H]-NAD+ (1.6 μCi/mmol), 200 nM biotinylated histone H1, 200 nM slDNA, and 1 nM PARP-1 or 4 nM PARP-2 enzyme. Autoreactions utilizing SPA bead-based detection are carried out in 100 μL volumes in white 96-well plates. Reactions are initiated by adding 50 μL of 2X NAD+ substrate mixture to 50 μL of 2× enzyme mixture containing PARP and DNA. These reactions are terminated by the addition of 150 μL of 1.5 mM benzamide (∼1 × 103-fold over its IC50). A 170 μL amount of the stopped reaction mixtures is transferred to streptavidin-coated Flash Plates, incubated for 1 hour, and counted using a TopCount microplate scintillation counter. Ki data are determined from inhibition curves at various substrate concentrations.
|
|
| In vivo |
A-966492 also demonstrates good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination and in an MX-1 breast cancer xenograft model both as a single agent and in combination. In addition, this compound has excellent pharmaceutical properties and has demonstrated in vivo efficacy in preclinical mouse tumor models in combination with TMZ, as well as single agent activity in a BRCA1-deficient MX-1 tumor model. It is further characterized in Sprague−Dawley rats, beagle dogs, and cynomolgus monkeys, with this chemical demonstrating oral bioavailabilities of 34−72% and half-lives of 1.7−1.9 hours. In vivo, it demonstrates significant enhancement of the efficacy of TMZ in a murine B16F10 syngeneic melanoma model, with the combination groups showing superior efficacy. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
What is the half-life of this compound?
Answer:
Sorry, Selleck don't have such information of this compound. But based on the reference: http://www.ncbi.nlm.nih.gov/pubmed/20337371, it may have half-life of 1.7−1.9 hours. “with this compound demonstrating oral bioavailabilities of 34−72% and half-lives of 1.7−1.9 hours (in vivo)” which is cited from the reference.